These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 20477432)
1. Complexities in drug trials: enrichment, biomarkers and surrogates. Interview with Robert Temple. Temple R Biomark Med; 2008 Apr; 2(2):109-12. PubMed ID: 20477432 [TBL] [Abstract][Full Text] [Related]
2. Interview with Janet Woodcock: progress on the FDA's critical path initiative. Woodcock J Biomark Med; 2009 Dec; 3(6):671-3. PubMed ID: 20477704 [TBL] [Abstract][Full Text] [Related]
5. ROBERT TEMPLE: an eye for data. Interview. Temple R Mol Interv; 2004 Dec; 4(6):313-7. PubMed ID: 15616158 [TBL] [Abstract][Full Text] [Related]
6. [80 years' of internal medicine education at the medical school of the university in Belgrade (1922-2002)]. Micić J; Micić D Srp Arh Celok Lek; 2003; 131(7-8):351-64. PubMed ID: 14692153 [TBL] [Abstract][Full Text] [Related]
7. On target? The challenge of integrating biomarker research in drug development. Interview with Walter Carney. Carney W Biomark Med; 2007 Jun; 1(1):17-21. PubMed ID: 20477457 [TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
9. Dale Schumacher on strategic quality planning and research. Interview by Joann Grenovich-Richards. Schumacher D J Healthc Qual; 2003; 25(4):16-8, 39. PubMed ID: 14606208 [TBL] [Abstract][Full Text] [Related]
10. Janet Woodcock discusses the FDA and the drug development process. Interview by Christopher Watson. Woodcock J Drug Discov Today; 2004 Jul; 9(13):548-50. PubMed ID: 15203087 [TBL] [Abstract][Full Text] [Related]
11. Interview: A private sector life in comparative effectiveness research. Interview with Robert W Dubois. Dubois RW J Comp Eff Res; 2013 Sep; 2(5):429-31. PubMed ID: 24236739 [TBL] [Abstract][Full Text] [Related]
12. James P. Bagian on patient safety initiatives. Interview by Deborah Mears. Bagian JP J Healthc Qual; 2002; 24(1):15-6, 24. PubMed ID: 11813529 [TBL] [Abstract][Full Text] [Related]
13. Voices from family medicine: Nikitas Zervanos. Interview by William B. Ventres and John J. Frey. Zervanos N Fam Med; 1992 Jul; 24(5):390-4. PubMed ID: 1526389 [TBL] [Abstract][Full Text] [Related]
14. [Frontier of mycobacterium research--host vs. mycobacterium]. Okada M; Shirakawa T Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793 [TBL] [Abstract][Full Text] [Related]
15. Perspectives on the draft ICH-M10 guidance: an interview with John Kadavil. Kadavil J Bioanalysis; 2019 Nov; 11(22):2027-2028. PubMed ID: 31637933 [TBL] [Abstract][Full Text] [Related]
16. The NCI All Ireland Cancer Conference. Johnston PG; Daly PA; Liu E Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862 [TBL] [Abstract][Full Text] [Related]
17. FDA explores new antiretroviral trial designs: interview with David Feigal, M.D. Interview by John S. James. Feigal D AIDS Treat News; 1997 Jun; (No 273):1-5. PubMed ID: 11364399 [TBL] [Abstract][Full Text] [Related]
18. Basic science and clinical trials: interview with William Paul, director of the Office of AIDS Research. Interview by John S James. Paul W AIDS Treat News; 1995 Feb; (no 217):1, 4-7. PubMed ID: 11362304 [TBL] [Abstract][Full Text] [Related]
19. Interview with Clemens Scherzer--searching for biomarkers in Parkinson's disease. Scherzer C Biomark Med; 2009 Apr; 3(2):113-4. PubMed ID: 20477503 [TBL] [Abstract][Full Text] [Related]
20. Advertising and promotion of medical devices. Portnoy S J Health Law; 2006; 39(2):265-82. PubMed ID: 17002234 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]